GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This 'first ...
Dosing was initiated in a Phase 1 single and multiple ascending dose study of SCY-247, the Company's second-generation triterpenoid antifungal in development for the treatment of severe invasive ...
Investing News Network on MSN6h
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 VaccinesLife science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...
Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback